Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment

Tong, Dali

doi:10.1136/jitc-2021-002944

Cited by 19 publications

(15 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 392 Moreover, SERMs in combination with immunotherapy were suggested to benefit patients with prostate cancer by regulating the tumor immune microenvironment. 393 …”

Section: Strategies and Challenges In The Management Of Osteoporosismentioning

confidence: 99%

Insights and implications of sexual dimorphism in osteoporosis

Zhang,

Xie,

Sun

et al. 2024

Bone Res

View full text Add to dashboard Cite

Osteoporosis, a metabolic bone disease characterized by low bone mineral density and deterioration of bone microarchitecture, has led to a high risk of fatal osteoporotic fractures worldwide. Accumulating evidence has revealed that sexual dimorphism is a notable feature of osteoporosis, with sex-specific differences in epidemiology and pathogenesis. Specifically, females are more susceptible than males to osteoporosis, while males are more prone to disability or death from the disease. To date, sex chromosome abnormalities and steroid hormones have been proven to contribute greatly to sexual dimorphism in osteoporosis by regulating the functions of bone cells. Understanding the sex-specific differences in osteoporosis and its related complications is essential for improving treatment strategies tailored to women and men. This literature review focuses on the mechanisms underlying sexual dimorphism in osteoporosis, mainly in a population of aging patients, chronic glucocorticoid administration, and diabetes. Moreover, we highlight the implications of sexual dimorphism for developing therapeutics and preventive strategies and screening approaches tailored to women and men. Additionally, the challenges in translating bench research to bedside treatments and future directions to overcome these obstacles will be discussed.

show abstract

“… 392 Moreover, SERMs in combination with immunotherapy were suggested to benefit patients with prostate cancer by regulating the tumor immune microenvironment. 393 …”

Section: Strategies and Challenges In The Management Of Osteoporosismentioning

confidence: 99%

Insights and implications of sexual dimorphism in osteoporosis

Zhang,

Xie,

Sun

et al. 2024

Bone Res

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is important to recognize the complexity of the modulation of PD-L1/PD-1 and CTLA-4/CD80 activities, as these processes can be influenced by various factors and signaling pathways. For example, the interactions between immune checkpoints and signaling pathways involving estrogen receptors or epidermal growth factor receptor (EGFR) 39 , 40 , as well as cytokines such as interleukin 6 (IL-6) 41 , play significant roles. It is important to note that some of the compounds used in the docking studies, such as quercetin and bazedoxifene, are direct inhibitors of EGFR 42 and IL-6R 43 , respectively.…”

Section: Discussionmentioning

confidence: 99%

Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules

Abramenko,

Vellieux,

Veselá

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Immune checkpoints regulate the immune system response. Recent studies suggest that flavonoids, known as phytoestrogens, may inhibit the PD-1/PD-L1 axis. We explored the potential of estrogens and 17 Selective Estrogen Receptor Modulators (SERMs) as inhibiting ligands for immune checkpoint proteins (CTLA-4, PD-L1, PD-1, and CD80). Our docking studies revealed strong binding energy values for quinestrol, quercetin, and bazedoxifene, indicating their potential to inhibit PD-1 and CTLA-4. Quercetin and bazedoxifene, known to modulate EGFR and IL-6R alongside estrogen receptors, can influence the immune checkpoint functionality. We discuss the impact of SERMs on PD-1 and CTLA-4, suggesting that these SERMs could have therapeutic effects through immune checkpoint inhibition. This study highlights the potential of SERMs as inhibitory ligands for immune checkpoint proteins, emphasizing the importance of considering PD-1 and CTLA-4 inhibition when evaluating SERMs as therapeutic agents. Our findings open new avenues for cancer immunotherapy by exploring the interaction between various SERMs and immune checkpoint pathways.

show abstract

“…However, the previous conventional understanding presented some contradictory results in the study of PCa [ 41 , 42 ]. PCa is usually considered a “cold tumour” [ 43 , 44 ]. Cold tumours are immunosuppressive tumours with fewer immune cells inside the tumour and in the TME, or immune cells are difficult to penetrate [ 40 ] (Fig.…”

Section: Single-cell Omics Analysis Of Time Of Pcamentioning

confidence: 99%

Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment

Liu

Gao

et al. 2023

Cell Mol Biol Lett

View full text Add to dashboard Cite

Prostate cancer is one of the more heterogeneous tumour types. In recent years, with the rapid development of single-cell sequencing and spatial transcriptome technologies, researchers have gained a more intuitive and comprehensive understanding of the heterogeneity of prostate cancer. Tumour-associated epithelial cells; cancer-associated fibroblasts; the complexity of the immune microenvironment, and the heterogeneity of the spatial distribution of tumour cells and other cancer-promoting molecules play a crucial role in the growth, invasion, and metastasis of prostate cancer. Single-cell multi-omics biotechnology, especially single-cell transcriptome sequencing, reveals the expression level of single cells with higher resolution and finely dissects the molecular characteristics of different tumour cells. We reviewed the recent literature on prostate cancer cells, focusing on single-cell RNA sequencing. And we analysed the heterogeneity and spatial distribution differences of different tumour cell types. We discussed the impact of novel single-cell omics technologies, such as rich omics exploration strategies, multi-omics joint analysis modes, and deep learning models, on future prostate cancer research. In this review, we have constructed a comprehensive catalogue of single-cell omics studies in prostate cancer. This article aimed to provide a more thorough understanding of the diagnosis and treatment of prostate cancer. We summarised and proposed several key issues and directions on applying single-cell multi-omics and spatial transcriptomics to understand the heterogeneity of prostate cancer. Finally, we discussed single-cell omics trends and future directions in prostate cancer.

show abstract

Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment

Cited by 19 publications

References 80 publications

Insights and implications of sexual dimorphism in osteoporosis

Insights and implications of sexual dimorphism in osteoporosis

Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules

Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment

Contact Info

Product

Resources

About